A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

NCT07018713

Status	RECRUITING
Phase	Phase 3
Sponsor	Merz Therapeutics GmbH
Enrollment	780 participants

Key Eligibility Criteria

Inclusion (4)

- Participant has a diagnosis of CM with or without aura according to the International Classification of Headache Disorders Edition 3 criteria for e 12 months and is able to distinguish migraine headaches from all other types of headaches;
- Participant age \< 50 years at the time of migraine onset;
- Participant meeting the following headache and migraine day criteria in each of the 3 months prior to screening: history of e 15 headache days per month and history of e 8 migraine days per month; and
- During the last 28 days of the screening period, participant experiencing: e 15 headache days and e 8 migraine days that qualify as such per the headache diary.

Exclusion (5)

- Diagnosis of other primary headache types, except tension-type headache, which is permitted;
- Diagnosis of aura without headache, migraine with brainstem aura, hemicrania continua, hypnic headache, hemiplegic migraine, retinal migraine, persistent aura without infarction, migraine aura-triggered seizure, or previous migrainous infarction;
- Diagnosis of secondary headache types, except medication overuse headache, which is permitted;
- Currently taking \> 1 prescribed drug for the preventive treatment of migraine;
- Discontinuation of anti-calcitonin gene-related peptide (CGRP) / anti-CGRP receptor monoclonal antibody treatment less than 5 months prior to screening.

Locations (100 total)

TrialSphere Corp, Merz Investigational Site #0010513, Chandler, Arizona, United States
Arizona Neuroscience Research, Merz Investigational Site #0010521, Phoenix, Arizona, United States
Baptist Health Medical Center, Merz Investigational Site #0010520, Little Rock, Arkansas, United States
... and 97 more locations